Skip to main content
Premium Trial:

Request an Annual Quote

Proteomics Expert Says Technology Lags Corporate Promises

PHILADELPHIA, May 17 – Many proteomics companies are promising more than they can deliver because they don’t yet have the technology to isolate and characterize low abundance proteins, Ian Humphery-Smith, a protein chemist at the University of Utrecht and the organizer of the Human Proteome Organization, said Thursday.

While companies, such as Large Scale Biology and Myriad, have touted the ability of their technology to pick out most of the proteins in certain cells, they haven’t identified more than five percent of the proteins in the human body, Humphery-Smith said.

“At present we’re at five percent and we’ve got 95 percent that are defying current technologies,” he told GenomeWeb, during a conference entitled "Proteomics: Delivering New Routes to Drug Discovery."

“Proteins are difficult…but for a number of reasons it’s not an easy job and [some companies are] overselling the deliverables,” he said. 

The problem, said Humphery-Smith, is that most cells overwhelmingly contain the same kind of proteins and important, low-abundance proteins are hard to pick out with current 2-D gel electrophoresis and mass spectrometry technology.

Solving this problem will require designing affinity agents, or molecules that capture certain classes of proteins, to screen out the high abundance proteins found in cells before analyzing the remaining proteins with mass spectrometry, he said.

“If you have antibodies or other ligands [to act as affinity agents], you have the potential to enrich your signal to do good mass spec,” he said. “But we can’t do PCR and we can’t hybridize [proteins to make them more easily identifiable] so we must have a ligand affinity enrichment of signal.”

Humphery-Smith also stressed that biological systems are naturally variable, and current 2-D gel and mass spec techniques for finding proteins must be repeated many times for the results to be statistically significant. Many proteomics researchers have overstated the significance of their results, he said, because they haven’t replicated their experiments often enough.

“If you’re going to conclude on the causalities of cancer and human ailments, you need large numbers of replicants,” he said.

Humphery-Smith said protein microarray technology is the most likely to discover therapeutically important proteins because it will allow researchers to precisely study how the proteins in cells change with disease.

Affymetrix will soon have a DNA microarray that covers the entire human genome, he said, and “we’ve got to compete with Affymetrix and others until we’ve got a reporter matrix that can look at your proteome in six organs, before and after dinner, seven days of the week, with three drugs.”

The Scan

Two J&J Doses

Johnson & Johnson says two doses of its SARS-CoV-2 vaccine provides increased protection against symptomatic COVID-19, CNN reports.

Pfizer-BioNTech Vaccine Response in Kids

The Pfizer-BioNTech SARS-CoV-2 vaccine in a lower-dose format appears to generate an immune response among children, according to the Washington Post.

Chicken Changes to Prevent Disease

The Guardian writes that researchers are looking at gene editing chickens to help prevent future pandemics.

PNAS Papers on Siberian Dog Ancestry, Insect Reproduction, Hippocampal Neurogenesis

In PNAS this week: ancestry and admixture among Siberian dogs, hormone role in fruit fly reproduction, and more.